Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue - Narrative (Details)

Revenue - Narrative (Details) $ / shares in Units, $ in Thousands, € in Millions														1 Months Ended							3 Months Ended
	Apr. 24, 2021 USD ($)	Apr. 01, 2021 USD ($) $ / shares shares	Mar. 24, 2021 USD ($) $ / shares shares	Feb. 08, 2018 USD ($) performanceObligation program swapOption researchProgram license	May 02, 2017 performanceObligation	May 02, 2017 USD ($) performanceObligation	May 02, 2017 researchProgram performanceObligation	May 02, 2017 license performanceObligation	May 02, 2017 performanceObligation	May 02, 2017 protein performanceObligation	May 02, 2017 leaseAgreement performanceObligation	Jan. 04, 2017 USD ($) preclinicalMilestone collaborationProduct bispecificTherapeuticProgram performanceObligation extensionOption product license	Jan. 04, 2017 EUR (€) preclinicalMilestone collaborationProduct bispecificTherapeuticProgram performanceObligation extensionOption product license	Mar. 31, 2021 USD ($)	Feb. 28, 2021	Feb. 29, 2020 collaborationProduct program	Feb. 28, 2019 USD ($)	Feb. 28, 2019 EUR (€)	Dec. 31, 2018 USD ($) preclinicalMilestone	Dec. 31, 2018 EUR (€) preclinicalMilestone	Mar. 31, 2021 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Jan. 01, 2019 USD ($)	May 02, 2017 collaborationProduct
Disaggregation of Revenue [Line Items]
Revenue recognized from contract with customer																					$ 800
Deferred revenues, current portion														$ 17,236							17,236				$ 12,627
Deferred revenue, net of current portion														32,315							32,315				$ 35,900
Number of technology licenses (in licenses) \| leaseAgreement											5
Total revenue																					15,633			$ 13,261
Number of separate performance obligations (in performance obligations) \| performanceObligation												1	1
Additions to deferred revenue																					4,000
Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations (in performance obligations) \| performanceObligation				3
Remaining performance obligation														22,800							22,800
Resale of stock period			60 days
Deferred revenues, current portion														10,200							10,200
Deferred revenue, net of current portion														9,400							9,400
Total revenue																					366			448
Seagen \| Private placement
Disaggregation of Revenue [Line Items]
Deferred revenue			$ 3,300
Shares of stock sold (in shares) \| shares			3,706,174
Shares of stock sold, net consideration			$ 13,000
Shares of stock sold, price per share (in dollars per share) \| $ / shares			$ 3.51
Fair value of stock (in dollars per share) \| $ / shares			$ 2.61
AstraZeneca
Disaggregation of Revenue [Line Items]
Deferred revenue														700							700
Remaining performance obligation														23,800							23,800
Revenue recognized from contract with customer																					100
Deferred revenues, current portion														900							900
Deferred revenue, net of current portion														18,100							18,100
Research collaboration agreement term					5 years
Total revenue														13,000							14,500			2,711
AstraZeneca \| Subsequent Event
Disaggregation of Revenue [Line Items]
Resale of stock period		60 days
Total revenue		$ 13,000
AstraZeneca \| Private placement \| Subsequent Event
Disaggregation of Revenue [Line Items]
Shares of stock sold (in shares) \| shares		3,584,230
Shares of stock sold, net consideration		$ 10,000
Shares of stock sold, price per share (in dollars per share) \| $ / shares		$ 2.79
Fair value of stock (in dollars per share) \| $ / shares		$ 2.60
Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Number of performance obligations (in performance obligations) \| performanceObligation												10	10
Remaining performance obligation														10,900							10,900
Revenue recognized from contract with customer																						$ 7,100
Deferred revenues, current portion														6,100							6,100
Deferred revenue, net of current portion														4,800							4,800
Number of novel proteins (in proteins) \| bispecificTherapeuticProgram												1	1
Number of research programs (in research programs) \| bispecificTherapeuticProgram												3	3
Number of programs (in programs) \| bispecificTherapeuticProgram												3	3
Total revenue																					767			10,102
Capitalized contract cost, net														100							100
Number of separate performance obligations (in performance obligations) \| performanceObligation												2	2
Number of combined performance obligations (in performance obligations) \| performanceObligation												2	2
Research term, extension period															12 months	12 months
Number of preclinical stage programs (in programs) \| program																2
Preclinical stage performance obligation period																60 days
Amortization of capitalized contract costs																								$ 100
Les Laboratoires Servier and Institut de Recherches Internationales Servier \| Research and Development Services
Disaggregation of Revenue [Line Items]
Research collaboration agreement term												3 years	3 years
Number of preclinical milestones (in preclinical milestones) \| preclinicalMilestone												2	2						1	1
License and Collaboration Agreement \| Seagen
Disaggregation of Revenue [Line Items]
Number of research programs (in research programs) \| researchProgram				3
Period after effective date agreements may be terminated				12 months
Contract termination advance notice period				90 days
Agreement termination advance notice period if marketing approval obtained				180 days
Agreement termination notice period upon material breach by the Company				90 days
Contract termination due to material breach, additional notice period if the breach is not susceptible				90 days
Number of licenses (in licenses) \| license				3
Number of swap options (in swap options) \| swapOption				2
Number of performance obligations (in performance obligations) \| performanceObligation				6
License and Collaboration Agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Period after effective date agreements may be terminated					12 months
Contract termination advance notice period					90 days
Agreement termination advance notice period if marketing approval obtained					180 days
Agreement termination notice period upon material breach by the Company					180 days
Contract termination due to material breach, additional notice period if the breach is not susceptible					180 days
Number of performance obligations (in performance obligations) \| performanceObligation									16
Number of novel proteins (in proteins) \| protein										4
Agreement termination notice period upon breach of payment obligations by the Company					30 days
Period of license performance obligation					12 months
License and Collaboration Agreement \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Number of licenses (in licenses) \| license												5	5
Number of performance obligations (in performance obligations) \| performanceObligation												4	4
Number of collaboration products (in collaboration products) \| collaborationProduct												2	2
Number of research programs (in research programs) \| bispecificTherapeuticProgram												5	5
Strategic Partnerships and Other License Agreements \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Period after effective date agreements may be terminated												12 months	12 months
Contract termination advance notice period												180 days	180 days
Revenue recognized from contract with customer																	$ 1,700	€ 1.5	$ 600	€ 0.5
Number of collaboration products (in collaboration products) \| product												4	4
Other arrangement \| Seagen
Disaggregation of Revenue [Line Items]
Number of research programs (in research programs) \| researchProgram				2
Platform technology license \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations (in performance obligations) \| performanceObligation				3
Number of target programs (in programs) \| program				3
Antibody target swap \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations (in performance obligations) \| performanceObligation				2
Governance committee participation \| Seagen
Disaggregation of Revenue [Line Items]
Number of performance obligations (in performance obligations) \| performanceObligation				1
Upfront Payment \| Seagen
Disaggregation of Revenue [Line Items]
Research and development services				$ 4,900
Deferred revenue				1,200,000
Upfront Payment \| Seagen \| License fees
Disaggregation of Revenue [Line Items]
Revenue				$ 30,000
Upfront Payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration						$ 45,000
Upfront Payment \| Les Laboratoires Servier and Institut de Recherches Internationales Servier \| License fees
Disaggregation of Revenue [Line Items]
Revenue												$ 32,000	€ 30.0
Additional other research services \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration						4,700
Servier Developed Collaboration Product \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Number of collaboration products (in collaboration products) \| collaborationProduct																1
Co-Development Collaboration Product \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Number of collaboration products (in collaboration products) \| collaborationProduct																1
Exclusive Product License Agreement \| Boston Pharmaceuticals \| Subsequent Event
Disaggregation of Revenue [Line Items]
Period after effective date agreements may be terminated	9 months
Contract termination advance notice period	60 days
Agreement termination advance notice period if marketing approval obtained	120 days
Agreement termination notice period upon material breach by the Company	180 days
Contract termination due to material breach, additional notice period if the breach is not susceptible	180 days
Collaborative arrangement, upfront payment	$ 10,000
Collaborative arrangement, potential additional consideration	$ 352,500
Agreement termination notice period due to non-payment of undisputed amounts	60 days
Estimated Development and Manufacturing Services \| Upfront Payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration						14,200
Milestone Payments \| Upfront Payment \| Seagen
Disaggregation of Revenue [Line Items]
Revenue recognized from contract with customer																					4,200
Allocable arrangement consideration																							$ 5,000
Milestone Payments \| Upfront Payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration						12,500
Estimated Phase 2a Services \| Upfront Payment \| AstraZeneca
Disaggregation of Revenue [Line Items]
Allocable arrangement consideration						$ 4,700
Agreement extension options (in extension options) \| Les Laboratoires Servier and Institut de Recherches Internationales Servier \| Research and Development Services
Disaggregation of Revenue [Line Items]
Research collaboration agreement term												1 year	1 year
Number of agreement extension options (in extension options) \| extensionOption												2	2
Minimum \| License and Collaboration Agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Number of collaboration products (in collaboration products) \| collaborationProduct																											2
Minimum \| Strategic Partnerships and Other License Agreements \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Agreement termination notice period upon material breach by the Company												90 days	90 days
Maximum \| License and Collaboration Agreement \| AstraZeneca
Disaggregation of Revenue [Line Items]
Number of collaboration products (in collaboration products)					4	4	4	4	4	4	4																4
Number of research programs (in research programs) \| researchProgram							2
Number of research licenses (in licenses)								4			4
Maximum \| Strategic Partnerships and Other License Agreements \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Agreement termination notice period upon material breach by the Company												120 days	120 days
Accounting Standards Update 2014-09 \| AstraZeneca
Disaggregation of Revenue [Line Items]
Capitalized contract cost, net														$ 700							$ 700					$ 1,600
Capitalized contract cost in accordance with ASC 340																										1,100
Accounting Standards Update 2014-09 \| Les Laboratoires Servier and Institut de Recherches Internationales Servier
Disaggregation of Revenue [Line Items]
Capitalized contract cost, net																										$ 500